Management provided an update on reimbursement and new products in the works for whole-genome karyotyping, carrier screening, and oncology.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
After reporting a sharp rise in revenues this week, Foundation Medicine discussed changes ahead for the company.
The company plans to bring both tissue-based and blood-based targeted sequencing tests through FDA clearance.
At the Molecular Medicine Tri-Conference, Guardant Health presented details from a 510-patient clinical validation study.
As AstraZeneca takes steps to reintroduce the EGFR-targeted NSCLC drug in the US, Qiagen will develop a tissue-based molecular CDx to accompany the launch.
Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis.
CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.
The partners hope to detect EGFR mutations in lung cancer patients using Trovagene's Precision Cancer Monitoring platform.
The assay analyzes circulating nucleic acids in blood samples to detect EGFR mutations in non-small cell lung cancer.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.